18 results about "Enterobacteriaceae bacterium" patented technology

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The application discloses an improved buffer protein peptone water culture medium and a preparation method and application thereof, and belongs to the technical field of microbial culture medium. The improved culture medium is based on a traditional buffer protein peptone water culture medium, and the ratio of nitrogen sources, the components and the concentration of a buffer system are optimized, and specific growth promoting factors are added, so that the problems of insufficient buffering capacity of the traditional culture medium, slow recovery of target strains and easy contamination of miscellaneous bacteria are solved. The culture medium has the advantages of stable buffering performance, high target strain proliferation efficiency and strong anti-pollution capacity, is suitable for pre-enrichment culture of enterobacteriaceae bacteria such as salmonella in food and environmental samples, and provides high-quality bacterial liquid basis for subsequent isolation and identification.

Provided is a method for detecting the presence or absence and / or amount of Enterobacteriaceae bacteria in a food or drink sample, an environmental sample, or a biological sample, in a short period of time, easily and efficiently. The method includes a step of simultaneously detecting the presence or absence and / or amount of at least two or more different genera of Enterobacteriaceae bacteria in a sample based on an antigen-antibody reaction.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

The invention relates to a method for the fermentative production of recombinant proteins using fnr mutants of E. coli. Using these strains, increased amounts of recombinant protein in the culture medium can be achieved compared to the prior art.

The invention relates to the field of bioengineering, and discloses a klebsiella pneumoniae H2208 strain and application thereof. The preservation number of the strain is GDMCC No: 65187; the kit comprises a tool plasmid pMar, has two T4SS gene clusters, and has efficient autonomous transfer efficiency. The strain or plasmid has the following characteristics: reverse mobilization of large non-zygotic plasmids enables host bacteria to directly obtain the large non-zygotic plasmids; and directly mobilizing the large non-zygotic plasmids to join and transfer the large non-zygotic plasmids into the recipient bacteria. According to the application, the pMar plasmid is used as the helper plasmid, large virulence plasmids in H2208 and large non-zygotic plasmids with homologous oriT sequences in other enterobacteriaceae bacteria can be efficiently transferred to recipient bacteria, and an effective tool is provided for researching the evolution and evolution laws and virulence and drug resistance formation mechanisms of various pathogenic bacteria.

The invention discloses a method for preparing a highly specific Salmonella pullorum plate agglutination antigen. The Salmonella pullorum C79-1 and C79-7 strains are revived and prepared into seed liquid, inoculated with a suitable culture medium, fermented and cultured according to a specific process, inactivated and centrifuged to collect the bacteria, and then washed at 121°C for 2 hours and multiple times to remove the protein antigen components that easily cross-react with Escherichia coli or other Enterobacteriaceae bacteria commonly found in the environment. The C79-1 and C79-7 strains are adjusted to a suitable bacterial concentration, Tween-20, crystal violet and glycerol are added, and the Salmonella pullorum plate agglutination antigen is obtained by sufficient homogenization. The antigen has higher specificity and is more accurate when used for pullorum purification detection. The bacterial yield according to the fermentation process is 4 times that of ordinary fermentation and 2 times that of solid culture. No ethanol precipitation is required, and the production cost is lower. Tween-20 is added to increase the surface tension of the antigen, solve the problem of difficulty in coating evenly during use, and provide a new and better diagnostic reagent for the purification of pullorum.

The purpose of the present invention is to provide a method for producing an animal model infected with Enterobacteriaceae bacteria such as pathogenic Escherichia coli. Provided is a method for producing an animal model infected with Enterobacteriaceae bacteria, the method comprising step (1) and step (2) in the following order. (1) A step for administering a β-lactam antibacterial agent to a non-human mammal; (2) a step including the following steps (2-1) and (2-2) in random order; (2-1) a step for administering at least one selected from the group consisting of lincomycin antibacterial agents and macrolide antibacterial agents to the non-human mammal; and (2-2) a step for administering Enterobacteriaceae bacteria to the non-human mammal

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

Antibiotic resistance leads to deadly hospital-acquired infections globally. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have identified priority bacteria, including Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, and particularly those carbapenem- resistant strains, also found in Enterobacterales (CRE) such as Escherichia coli and Klebsiella, as requiring new antibiotics. The present disclosure provides a chemical class of drugs less susceptible to existing mechanisms of antibiotic resistance and targeting difficult-to-treat bacterial infections. It more particularly provides compounds of formula (I), and compositions and uses thereof.

The invention belongs to the technical field of medical application, particularly discloses novel application of loratadine in a colistin synergist, and discloses a loratadine-colistin composition and a compound preparation, and the mass ratio of loratadine to colistin is (8-512): 1. The combination of the loratadine and the colistin can obviously enhance the antibacterial activity of the colistin on enterobacteriaceae bacteria, and the FICI is 0.0938-0.1563 (both less than 0.5), that is, the combination of the loratadine and the colistin shows an obvious synergistic effect. Meanwhile, the synergist can effectively reduce the use amount of the colistin, and the use amount of the colistin used independently is 4-32 times of the use amount of the loratadine and the colistin used jointly. The bactericidal composition can play a role in synergistically reversing drug resistance, the FICI is 0.0938-0.1563, and the bactericidal composition shows an obvious bactericidal effect after 2-4 hours after drug combination.

The invention discloses a chelating type composite micelle with Gram-negative bacterium antibacterial activity, which comprises metal ions, macromolecules with chelating blocks and an antibacterial agent with Lewis base functional groups, the antibacterial agent has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB), and the chelating type composite micelle has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB) and has the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB) and the antibacterial activity of multiple drug-resistant Gram-negative bacteria (MDR-GNB). Such as carbapenem resistant Acinetobacter baumannii, Pseudomonas aeruginosa or Enterobacteriaceae bacteria.

The invention discloses a carbapenem-resistant enterobacteriaceae bacterium sensitivity detection kit and a detection method, the detection kit comprises a reaction liquid, a drug sensitivity detection plate, a first group of antibiotics, a second group of antibiotics and a third group of antibiotics, the drug sensitivity detection plate is provided with a positive hole, a negative hole, a first experiment group hole, a second experiment group hole and a third experiment group hole; the first group of antibiotics is embedded in the first experimental group hole in a manner that the mass is in gradient change, and the first group of antibiotics is epracycline; the second group of antibiotics is embedded in the second experimental group holes in a mass gradient change manner, and the second group of antibiotics is ceftazidime; the third group of antibiotics is embedded in the holes of the third experimental group in a mass gradient change manner, and the third group of antibiotics is a combination of ceftazidime and aztreonam; the reaction liquid comprises glucose and a pH indicator. The detection kit provided by the invention can accurately and rapidly detect the sensitivity of CRE to CZA, CZA + ATM and ERV.

The invention belongs to the field of gene engineering, and particularly relates to a plasmid system for traceless gene editing and drug-resistant plasmid removal in enterobacteriaceae bacteria and application of the plasmid system. The invention provides a set of multifunctional tool plasmid system capable of rapidly editing genes in enterobacteriaceae bacteria and removing plasmids, which comprises pGGTOX plasmids with gene editing and plasmid removing functions, and pCP-oriT plasmids for eliminating resistance genes to realize traceless gene knockout, and gene editing and plasmid elimination in enterobacteriaceae bacteria can be carried out within 3-4 days as soon as possible by using a homologous recombination principle, so that a brand new idea is provided for construction of a multifunctional tool plasmid system, and the method has a good application prospect.

The invention discloses an application of Incyclinide and colistin in preparation of a bactericidal drug for enterobacteriaceae bacteria carrying a mcr (mcr) gene. Incyclinide (Ini) is a chemically modified tetracycline derivative, the invention proves that Ini can recover the bactericidal effect of colistin on enterobacteriaceae bacteria carrying mcr genes in vitro and in animal models, and mechanism analysis shows that Ini recovers the drug effect of colistin by inhibiting lipid A modification, inducing oxidative damage and dissipating proton power (PMF). As a colistin adjuvant, Ini has huge potential in the aspect of resisting enterobacteriaceae bacteria carrying mcr genes.

The present invention relates to an isolated strain of lactic acid bacteria (LAB) for inhibiting drug-resistant Enterobacteriaceae, in which the isolated strain of the LAB includes Lactobacillus rhamnosus JJ101, Lactobacillus paracasei JJ102 and / or Lactobacillus plantarum JJ103, and the isolated strain of the LAB inhibit growth of the drug-resistant Enterobacteriaceae. After orally administered to a subject, the isolated strain of the LAB can inhibit the growth of the drug-resistant Enterobacteriaceae, and thus can potentially be used to prevent, improve and / or treat the infection of the drug-resistant Enterobacteriaceae.

Packaged dog chew toy made from one or more pieces of antler, animal bone pieces or other animal by-products of Category 3, characterized by a partially sterilized state such that Salmonella or Enterobacteriaceae are killed.